We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company which develops targeted medicines for cancer and other proliferative diseases. It develops several families of anticancer drugs that act on the cell cycle, including nucleoside analogs, CDK (cyclin dependent kinase) inhibitor... Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company which develops targeted medicines for cancer and other proliferative diseases. It develops several families of anticancer drugs that act on the cell cycle, including nucleoside analogs, CDK (cyclin dependent kinase) inhibitors, and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include CYC065 CDK inhibitor, Sapacitabine and seliciclib, CYC682, CYC140 PLK inhibitor, and CYC202. It earns the majority of its revenue from the United Kingdom. Show more
BERKELEY HEIGHTS, N.J., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing...
BERKELEY HEIGHTS, N.J., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing...
- Oral Fadraciclib Phase 2 Proof of Concept Study Enrolling Well -- 065-101 PoC Interim Data Anticipated in the Fourth Quarter of 2024 -- Management to Host Conference Call at 4:30 pm EDT Today...
BERKELEY HEIGHTS, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing...
BERKELEY HEIGHTS, N.J., June 26, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing...
Β - Novel CDK2/9 inhibitor fadraciclib induces anaphase catastrophe, a novel cancer-specificΒ mechanism of action - BERKELEY HEIGHTS, N.J., June 04, 2024 (GLOBE NEWSWIRE) -- Cyclacel...
- Clinical, PK and PD data from novel CDK2/9 inhibitor fadraciclib monotherapy studies support ongoing proof of concept study in patients with solid tumors and lymphoma - BERKELEY HEIGHTS, N.J...
- New Clinical Data to be Presented at ASCO Annual MeetingΒ Highlighting Potential Precision Medicine Strategy with Oral Fadraciclib -- First Patients Enrolled in Oral Fadraciclib Phase 2 Proof of...
BERKELEY HEIGHTS, N.J., May 08, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing...
BERKELEY HEIGHTS, N.J., May 02, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.08 | -7.47663551402 | 1.07 | 1.1 | 0.98 | 29531 | 1.01481758 | CS |
4 | -0.25 | -20.1612903226 | 1.24 | 1.26 | 0.9517 | 34219 | 1.06540966 | CS |
12 | -0.67 | -40.3614457831 | 1.66 | 1.87 | 0.9517 | 57433 | 1.40551629 | CS |
26 | -1.18 | -54.3778801843 | 2.17 | 4 | 0.9517 | 466977 | 2.21656968 | CS |
52 | -3.99 | -80.1204819277 | 4.98 | 11.343 | 0.9517 | 324182 | 2.87762797 | CS |
156 | -78.06 | -98.7476280835 | 79.05 | 91.5 | 0.9517 | 266695 | 15.54389549 | CS |
260 | -125.01 | -99.2142857143 | 126 | 293.9607 | 0.9517 | 300470 | 59.40877487 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions